Pfizer (NYSE:PFE) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Pfizer (NYSE:PFE - Free Report) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued a neutral rating and a $24.00 price objective on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for Pfizer's FY2025 earnings at $2.99 EPS.

A number of other equities research analysts have also recently weighed in on the company. UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.57.

Pfizer Stock Up 0.7 %

Shares of PFE traded up $0.17 during mid-day trading on Tuesday, hitting $22.95. 35,816,572 shares of the company's stock were exchanged, compared to its average volume of 40,554,253. The company has a 50-day simple moving average of $24.58 and a 200 day simple moving average of $25.97. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $130.16 billion, a PE ratio of 16.28, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 earnings per share. On average, research analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.49%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 121.99%.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

Several institutional investors have recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $28,000. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.